| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDH22 |
| Uniprot No | Q9UJ99 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-828aa |
| 氨基酸序列 | MRPRPEGRGLRAGVALSPALLLLLLLPPPPTLLGRLWAAGTPSPSAPGARQDGALGAGRVKRGWVWNQFFVVEEYTGTEPLYVGKIHSDSDEGDGAIKYTISGEGAGTIFLIDELTGDIHAMERLDREQKTFYTLRAQARDRATNRLLEPESEFIIKVQDINDSEPRFLHGPYIGSVAELSPTGTSVMQVMASDADDPTYGSSARLVYSVLDGEHHFTVDPKTGVIRTAVPDLDRESQERYEVVIQATDMAGQLGGLSGSTTVTIVVTDVNDNPPRFPQKMYQFSIQESAPIGTAVGRVKAEDSDVGENTDMTYHLKDESSSGGDVFKVTTDSDTQEAIIVVQKRLDFESQPVHTVILEALNKFVDPRFADLGTFRDQAIVRVAVTDVDEPPEFRPPSGLLEVQEDAQVGSLVGVVTARDPDAANRPVRYAIDRESDLDQIFDIDADTGAIVTGKGLDRETAGWHNITVLAMEADNHAQLSRASLRIRILDVNDNPPELATPYEAAVCEDAKPGQLIQTISVVDRDEPQGGHRFYFRLVPEAPSNPHFSLLDIQDNTAAVHTQHVGFNRQEQDVFFLPILVVDSGPPTLSSTGTLTIRICGCDSSGTIQSCNTTAFVMAASLSPGALIALLVCVLILVVLVLLILTLRRHHKSHLSSDEDEDMRDNVIKYNDEGGGEQDTEAYDMSALRSLYDFGELKGGDGGGSAGGGAGGGSGGGAGSPPQAHLPSERHSLPQGPPSPEPDFSVFRDFISRKVALADGDLSVPPYDAFQTYAFEGADSPAASLSSLHSGSSGSEQDFAYLSSWGPRFRPLAALYAGHRGDDEAQAS |
| 预测分子量 | 89 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDH22重组蛋白的参考文献示例(注：部分文献信息可能为模拟或需进一步核实，建议通过学术数据库确认)：
---
1. **《重组CDH22蛋白在肿瘤细胞侵袭中的功能研究》**
作者：李明等
摘要：研究通过哺乳动物表达系统成功制备了CDH22重组蛋白，发现其能够抑制乳腺癌细胞MDA-MB-231的侵袭能力，可能与调控上皮-间质转化(EMT)相关信号通路有关。
2. **《CDH22重组蛋白的体外表达及纯化优化》**
作者：王华等
摘要：利用昆虫杆状病毒系统表达CDH22胞外域重组蛋白，通过亲和层析和凝胶过滤纯化获得高纯度蛋白，为后续研究其结构与功能奠定基础。
3. **《CDH22与神经退行性疾病的相关性：基于重组蛋白的相互作用分析》**
作者：张磊等
摘要：研究通过表面等离子共振技术(SPR)证实CDH22重组蛋白与β-淀粉样蛋白存在特异性结合，提示其在阿尔茨海默病病理过程中可能发挥作用。
4. **《CDH22重组蛋白的免疫调节功能及其在自身免疫疾病中的应用潜力》**
作者：陈芳等
摘要：在小鼠模型中验证了CDH22重组蛋白通过抑制T细胞过度活化减轻类风湿性关节炎症状，表明其具有免疫治疗应用前景。
---
**注意**：上述文献为示例性质，实际研究中请通过PubMed、CNKI等学术平台检索最新及真实发表的论文。若需具体文献，建议提供更详细的研究方向以便精准查找。
CDH22 (cadherin-22), a member of the cadherin superfamily, is a calcium-dependent cell adhesion protein implicated in mediating intercellular interactions and tissue morphogenesis. Classified as a type II classical cadherin, it shares structural features with other cadherins, including extracellular calcium-binding repeats, a transmembrane domain, and a cytoplasmic domain that interacts with catenins to link the cytoskeleton. CDH22 is less characterized compared to well-studied cadherins like E-cadherin or N-cadherin, but emerging studies suggest its role in neural development, cancer progression, and immune regulation.
Recombinant CDH22 protein is engineered for in vitro studies to elucidate its biological functions. Produced using expression systems like mammalian cells or *E. coli*, the recombinant form retains key domains for adhesion and signaling. Researchers utilize it to investigate binding partners, signaling pathways (e.g., Wnt/β-catenin), and its dual role in cell aggregation or repulsion, which may depend on cellular context. In cancer, CDH22 shows conflicting roles: some studies associate its downregulation with tumor metastasis, while others propose it as a pro-invasive factor in gliomas or pancreatic cancer. Its expression in specific brain regions also hints at neurodevelopmental relevance.
Current applications of recombinant CDH22 include antibody development, mechanistic studies of cell-cell communication, and exploring its potential as a therapeutic target. However, its precise physiological and pathological mechanisms remain unclear, necessitating further research to clarify its context-dependent functions and therapeutic implications.
×
